지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2007.10
- 수록면
- 294 - 301 (8page)
이용수
초록· 키워드
오류제보하기
Purpose: Docetaxel (Taxotere<SUP>ⓡ</SUP>) and capecitabine are used in combination to treat advanced gastric cancer. Thymidine phosphorylase (TP) is an essential enzyme for the activation of capecitabine in tumors. This study sought to identify the best combination therapy with capecitabine and using two different schedules for docetaxel, a TP up-regulator, to enhance capecitabine’s efficacy.
Methods: The human gastric cancer cell line SNU-484 was cultured and docetaxel (2㎍/㎖) was added to the 24-well plates that contained 5×105 cells/well. The total RNA was isolated and RT-PCR was done to identify the TP expression. Four- or five-week-old BALB/c-nu/nu mice were subcutaneously inoculated with the SNU-484 cells. The nude mice were divided into two groups and they were given capecitabine 539 ㎎/㎡ p.o. from days 1 to 14: Group 1 was given docetaxel 15 ㎎/㎡ i.v. on day 1; Group 2 was given docetaxel 7.5㎎/㎡ on days 1 and 8. Tumor tissues were excised on days 1, 8 and 15 to measure the TP and bcl-2 levels.
Results: TP was expressed 2 hours after docetaxel administration. Group 2 had a higher TP concentration in the tumor tissues and a better antitumor effect than did Group 1. There was no difference in the bcl-2 concentration in the two groups.
Conclusion: These results suggest that docetaxel stimulates the TP expression in tumor tissues and it enhances the antitumor activity of capecitabine. A weekly docetaxel injection with capecitabine administration can be used to treat gastric cancer more effectively than when docetaxel is injected once per cycle. Capecitabine had no bcl-2 suppressive effect in this study.
Methods: The human gastric cancer cell line SNU-484 was cultured and docetaxel (2㎍/㎖) was added to the 24-well plates that contained 5×105 cells/well. The total RNA was isolated and RT-PCR was done to identify the TP expression. Four- or five-week-old BALB/c-nu/nu mice were subcutaneously inoculated with the SNU-484 cells. The nude mice were divided into two groups and they were given capecitabine 539 ㎎/㎡ p.o. from days 1 to 14: Group 1 was given docetaxel 15 ㎎/㎡ i.v. on day 1; Group 2 was given docetaxel 7.5㎎/㎡ on days 1 and 8. Tumor tissues were excised on days 1, 8 and 15 to measure the TP and bcl-2 levels.
Results: TP was expressed 2 hours after docetaxel administration. Group 2 had a higher TP concentration in the tumor tissues and a better antitumor effect than did Group 1. There was no difference in the bcl-2 concentration in the two groups.
Conclusion: These results suggest that docetaxel stimulates the TP expression in tumor tissues and it enhances the antitumor activity of capecitabine. A weekly docetaxel injection with capecitabine administration can be used to treat gastric cancer more effectively than when docetaxel is injected once per cycle. Capecitabine had no bcl-2 suppressive effect in this study.
목차
서론
방법
결과
고찰
결론
REFERENCES
참고문헌 (24)
참고문헌 신청
1. [보고서] - Government of the Republic of Korea / 2005 / Annual report on the cause of death statistics
2. [학술지(정기간행물)] - Kano Y / 1996 / Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro / Br J Cancer 74 : 704 ~ 710
3. [학술지(정기간행물)] - Johnson KR / 1997 / 5-Fluorouracil interferes with paclitaxel cytotoxicity against human solid tumor cells / Clin Cancer Res 3 : 1739 ~ 1745
4. [학술지(정기간행물)] - Johnson KR / 1999 / Antagonistic interplay between antimitotic and G1-S arresting agents observed in experimental combination therapy / Clin Cancer Res 5 : 2559 ~ 2565
5. [학술지(정기간행물)] - Sawada N / 1998 / Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer? xenografts / Clin Cancer Res 4 : 1013 ~ 1019
2. [학술지(정기간행물)] - Kano Y / 1996 / Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro / Br J Cancer 74 : 704 ~ 710
3. [학술지(정기간행물)] - Johnson KR / 1997 / 5-Fluorouracil interferes with paclitaxel cytotoxicity against human solid tumor cells / Clin Cancer Res 3 : 1739 ~ 1745
4. [학술지(정기간행물)] - Johnson KR / 1999 / Antagonistic interplay between antimitotic and G1-S arresting agents observed in experimental combination therapy / Clin Cancer Res 5 : 2559 ~ 2565
5. [학술지(정기간행물)] - Sawada N / 1998 / Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer? xenografts / Clin Cancer Res 4 : 1013 ~ 1019
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Modified Docetaxel and Cisplatin in Combination with Capecitabine (DCX) as a First-Line Treatment in HER2-Negative Advanced Gastric Cancer
Asian Pacific journal of cancer prevention : APJCP
2014 .01
-
Phase I Study of the Escalation of Docetaxel with Fixed Dose of TS1 in Advanced Gastric Cancer
대한임상약리학회 학술대회
2005 .01
-
비소세포성 폐암환자에서의 Docetaxel과 Cisplatin의 복합요법에 대한 효과
한국임상약학회지
2002 .01
-
Optimal Timing for the Administration of Capecitabine with Preoperative Chemoradiation for Locally Advanced Rectal Cancer
Cancer Research and Treatment
2006 .01
-
진행성 비소세포폐암의 이차항암화학요법으로서 Docetaxel 단독요법의 성적
Tuberculosis and Respiratory Diseases
2005 .01
-
The Safety and Efficacy of Second-line Single Docetaxel (75 mg/m2) Therapy in Advanced Non-Small Cell Lung Cancer Patients who were Previously Treated With Platinum-based Chemotherapy
Cancer Research and Treatment
2005 .01
-
Docetaxel-Aggravated Psoriasis
Annals of Dermatology
2019 .01
-
Clinical Effects of The Combination Chemotherapy of Docetaxel and Cisplatin in Non-Small Cell Lung Cancer
대한약학회 학술대회
2001 .01
-
ABT-737 ameliorates docetaxel resistance in triple negative breast cancer cell line
Annals of Surgical Treatment and Research
2018 .11
-
A Case Report of Improvement of Docetaxel-induced Fluid Retention in a Patient with Advanced Gastric Cancer using Herbal Decoction, Modified Bangkihwangki-tang
대한한의학회지
2014 .12
-
위암 침윤 염증세포의 thymidine phosphorylase (TP): TP의 예후와 종양 신혈관생성과의 관계
대한내과학회지
2005 .01
-
Effects of combination therapy of docetaxel with selenium on the human breast cancer cell lines MDA-MB-231 and MCF-7
Annals of Surgical Treatment and Research
2015 .01
-
Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)
Cancer Research and Treatment
2019 .01
-
Capecitabine Pattern of Usage, Rate of Febrile Neutropaenia and Treatment Related Death in Asian Cancer Patients in Clinical Practice
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Genetic Variations of Drug Transporters Can Influence on Drug Response in Patients Treated with Docetaxel Chemotherapy
Cancer Research and Treatment
2015 .01
-
Effect of time interval between capecitabine intake and radiotherapy on local recurrence-free survival in preoperative chemoradiation for locally advanced rectal cancer
Radiation oncology journal : ROJ
2017 .01
-
A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer
Cancer Research and Treatment
2012 .01
-
A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer
Cancer Research and Treatment
2015 .01
이 논문의 저자 정보
이 논문과 함께 이용한 논문
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2013-514-002670962